Neuland Laboratories is accelerating the expansion of its peptide manufacturing capabilities to meet growing customer demand, with the first of four planned modules at its commercial peptide manufacturing site in Hyderabad now operational.
Module one provides a total reactor capacity of 7,000 litres, comprising 750 litres for solid-phase peptide synthesis (SPPS) and 6,250 litres for liquid-phase peptide synthesis (LPPS). The facility will support customer programmes ranging from small-scale development to multikilogram production of complete peptide active pharmaceutical ingredients (APIs), including complex and long-chain peptides, as well as commercial-scale production of crude peptides.
The SPPS and LPPS reactors are housed in separate suites, enabling parallel operations, and are supported by three DAC columns — one 45 cm and two 60 cm — along with two lyophilisers with capacities of 100 litres and 200 litres.
Following an investment of $30 million in module one, Neuland said further investments in subsequent modules will be aligned with evolving customer requirements.
The foundational infrastructure for module two is already in place, and the company expects to begin work ahead of its original timeline once customer requirements are finalised. Its configuration, instrumentation and capacity are currently being defined in collaboration with the customer whose projects will anchor the expanded capability.
Module two is planned to provide an overall reactor capacity of up to 18,000 litres, including three 5,000-litre LPPS reactors, either a 1,000-litre or 2,000-litre SPPS reactor, and smaller reactors of up to 1,000 litres. The flexible configuration is intended to support a broad range of peptide programmes and production scales.
Neuland said the therapeutic focus of its partner programmes is also broadening beyond obesity and metabolic diseases, with oncology emerging as a particularly active area of early-stage development.
The company noted that as peptide pipelines expand, an increasing number of biotech companies are struggling to access capable outsourced development and commercial manufacturing capacity.
Looking ahead, Neuland said it is already exploring options to address future demand.
“Our goal is to ensure we have the capacity to meet customer demand not just over the next 24 months, but over the next decade, as we deepen our strategic partnerships with leading pharma and biotech companies,” said Saharsh Davuluri, CEO and Managing Director, Neuland Laboratories.
Module One is supported by a team of nearly 212 peptide specialists. The expansion comes as Neuland has reported strong recent growth, with revenues increasing 116% in its most recent quarterly results, driven primarily by higher commercial contract volumes and an increasing number of clinical projects.
Neuland Laboratories is a specialist API contract development and manufacturing organisation (CDMO) serving pharmaceutical and biotechnology companies. The company provides process development and commercial supply services for complex molecules and new chemical entities, and serves customers across more than 80 countries.
Neuland operates three US FDA- and EU GMP-compliant manufacturing facilities in India, with a combined reactor capacity of approximately 1,218 kL. In 2026, the company invested in a new commercial-scale peptide manufacturing facility and is also developing a dedicated R&D process development centre in Hyderabad.
The company has filed more than 1,000 drug master files (DMFs) globally and offers more than 100 APIs across multiple therapeutic areas.
